Drug Profile
Research programme: RNA interference-based therapeutics - Celera/Merck
Latest Information Update: 03 Aug 2010
Price :
$50
*
At a glance
- Originator Celera Diagnostics
- Developer Merck & Co
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2010 Discontinued for Cancer in USA (Parenteral)
- 10 Apr 2008 Early research in Cancer in USA (Parenteral)